Paper39300079
Current status and research directions in acute myeloid leukemia.
Kantarjian H and 10 others. Blood Cancer J, 2024. Cited by 115 papers, by iCite.
Cite this record
ConductScience Library. Current status and research directions in acute myeloid leukemia. Papers, record 39300079. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39300079
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Humans | |
| Molecular Targeted Therapy | |
| Antineoplastic Agents |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA016672 | NIH |
Source NIH RePORTER
References181
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31088841 | Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31088841 | PubMed |
| 2 | 24346116 | Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24346116 | PubMed |
| 3 | 37379495 | Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/37379495 | PubMed |
| 4 | 16728980 | Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. | Leukemia | 2006 | https://conductscience.org/library/papers/16728980 | PubMed |
| 5 | 25809968 | Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. | Cancer | 2015 | https://conductscience.org/library/papers/25809968 | PubMed |
| 6 | 35772432 | Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. | Lancet Haematol | 2022 | https://conductscience.org/library/papers/35772432 | PubMed |
| 7 | 15187030 | Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. | Blood | 2004 | https://conductscience.org/library/papers/15187030 | PubMed |
| 8 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 9 | 37187198 | Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. | Lancet Haematol | 2023 | https://conductscience.org/library/papers/37187198 | PubMed |
| 10 | 34043428 | Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34043428 | PubMed |
| 11 | 33681815 | Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. | Blood Cancer Discov | 2021 | https://conductscience.org/library/papers/33681815 | PubMed |
| 12 | 33374216 | Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33374216 | PubMed |
| 13 | 37003279 | Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. | Lancet Haematol | 2023 | https://conductscience.org/library/papers/37003279 | PubMed |
| 14 | 38583455 | Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. | Lancet Haematol | 2024 | https://conductscience.org/library/papers/38583455 | PubMed |
| 15 | 12393590 | All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. | Blood | 2002 | https://conductscience.org/library/papers/12393590 | PubMed |
| 16 | 36892949 | Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. | Cancer | 2023 | https://conductscience.org/library/papers/36892949 | PubMed |
| 17 | 29601269 | Molecular Minimal Residual Disease in Acute Myeloid Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29601269 | PubMed |
| 18 | 25833957 | A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. | Blood | 2015 | https://conductscience.org/library/papers/25833957 | PubMed |
| 19 | 32561839 | The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. | Leukemia | 2021 | https://conductscience.org/library/papers/32561839 | PubMed |
| 20 | 38113472 | Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. | Blood Adv | 2024 | https://conductscience.org/library/papers/38113472 | PubMed |
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 115 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42957740 | Deep learning predicts IDH1 mutation status in acute myeloid leukemia from bone marrow smears. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42957740 | PubMed |
| 42882927 | Clinical and Treatment-Related Factors Associated with Neutrophil Recovery After Bloodstream Infection in Acute Leukemia: A Competing-Risk Analysis. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882927 | PubMed |
| 42882877 | Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882877 | PubMed |
| 42864652 | CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML. | Genome Med | 2026 | https://conductscience.org/library/papers/42864652 | PubMed |
| 42801107 | Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42801107 | PubMed |
| 42724439 | Association between the systemic immune-inflammation index and overall survival in patients with leukemia: a multicenter cohort study. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724439 | PubMed |
| 42722966 | Treatment Preferences for Acute Myeloid Leukemia in Harbin, China: A Discrete Choice Experiment Among Patients, Caregivers, and Hematologists. | Patient | 2026 | https://conductscience.org/library/papers/42722966 | PubMed |
| 42690491 | High expression of CD74 is associated with poor prognosis and tumor immune infiltration in Acute Myeloid Leukemia. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42690491 | PubMed |
| 42680202 | Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42680202 | PubMed |
| 42527666 | Adaptor-mediated rewiring of FLT3 signaling engages p38 MAPK to sustain gilteritinib resistance in acute myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/42527666 | PubMed |
| 42452347 | Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin. | J Clin Med | 2026 | https://conductscience.org/library/papers/42452347 | PubMed |
| 42368576 | Lactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42368576 | PubMed |
| 42365365 | Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42365365 | PubMed |
| 42338241 | Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation. | Immunology | 2026 | https://conductscience.org/library/papers/42338241 | PubMed |
| 42323414 | SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42323414 | PubMed |
| 42291184 | ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance. | iScience | 2026 | https://conductscience.org/library/papers/42291184 | PubMed |
| 42265394 | Conception-calibrated male pediatric tumor mitotic clocks. | Commun Biol | 2026 | https://conductscience.org/library/papers/42265394 | PubMed |
| 42255490 | Integrative Analysis of Genetic Risk Factors for Acute Myeloid Leukemia Using Mendelian Randomization and Single-Cell RNA Sequencing Validation. | Int J Genomics | 2026 | https://conductscience.org/library/papers/42255490 | PubMed |
| 42211128 | LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia. | iScience | 2026 | https://conductscience.org/library/papers/42211128 | PubMed |
| 42192458 | Heat shock protein 60-targeted peptide-conjugated platinum nanozyme: redox regulation by multi-enzyme activities induces mitochondrial reprogramming and acute leukemia cells fate switch. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42192458 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| CD33 | 945 | PubTator's text mining | https://conductscience.org/library/genes/945 | NCBI Gene |
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| IDH2 | 3418 | PubTator's text mining | https://conductscience.org/library/genes/3418 | NCBI Gene |
| IL3RA | 3563 | PubTator's text mining | https://conductscience.org/library/genes/3563 | NCBI Gene |
| MEN1 | 4221 | PubTator's text mining | https://conductscience.org/library/genes/4221 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39300079
GET https://conductscience.org/api/papers/v1/39300079/references?page=2